ER+ Basal prevalence is double amongst Black women compared to White women.1
The BluePrint 80-gene subtyping assay enables you to uncover aggressive ER+ Basal tumors to help prevent undertreatment.
Black women have a significantly higher proportion of High Risk HR+/Basal and HR-/Basal tumors compared to White women
(Reid et al., ASCO 2022)
- MP + BP more precisely stratify tumors resulting in distinct 3- and 10-year outcomes, independent of race, beyond clinical subtype alone (Reid et al., ESMO 2024, #210P, Reid et al., SABCS 2023)
- Black patients with Low Risk, Luminal A-Type tumors had excellent 10-year survival outcomes, similar to outcomes observed in MINDACT, where the patient cohort was predominantly white, suggesting equivalent outcomes among diverse patients when classified by MP and BP (Reid et al., SABCS 2023)
Dive deeper into the data with our Medical team
Request Data Review / Additional Data:
